Key result
Surgery plus adjuvant carboplatin and paclitaxel shows no recurrence at six months in primary ovarian angiosarcoma.
Why the study?
Primary angiosarcoma of the ovary is an exceptionally rare and aggressive malignancy with lacking standardized management protocols and poor prognosis.
Case Report (n=1)
This case report demonstrates the short-term efficacy of surgery combined with adjuvant carboplatin and paclitaxel for a rare primary ovarian angiosarcoma, while highlighting the necessity of immunohistochemistry for accurate diagnosis.
May support adjuvant carboplatin-paclitaxel after surgery for ovarian angiosarcoma; hypothesis-generating while emphasizing immunohistochemistry for accurate diagnosis.
Introduction: Primary angiosarcoma of the ovary is an exceptionally rare and aggressive malignancy, representing a diagnostic and therapeutic challenge. Due to its rarity, standardized management protocols are lacking, and prognosis remains poor. Case Presentation: A 45-year-old woman with diabetes and hypertension presented with abdominal pain and a palpable pelvic mass. Imaging revealed a complex right adnexal mass. She underwent total abdominal hysterectomy with bilateral salpingo-oophorectomy. Histopathological examination revealed a high-grade pleomorphic tumor. Immunohistochemistry was pivotal for diagnosis, showing strong positivity for CD31 and ERG, and negativity for epithelial markers, confirming a primary pure ovarian angiosarcoma (FIGO Stage II). Postoperative PET-CT showed no distant metastasis. Following a multidisciplinary tumor board review, she received four cycles of adjuvant carboplatin and paclitaxel. At six-month follow-up, she remained asymptomatic with no evidence of recurrence. Conclusion: This case underscores the importance of a comprehensive immunohistochemical panel in diagnosing rare ovarian malignancies, particularly to distinguish angiosarcoma from other poorly differentiated tumors. Multidisciplinary management is essential. While adjuvant chemotherapy may offer benefit, the prognosis for advanced-stage ovarian angiosarcoma remains guarded. This report adds to the limited literature on this entity and highlights the need for further research to establish optimal treatment strategies.
No takes yet. Share an insight, caveat, or question.
Eid et al. (2026) conducted a case report in Primary angiosarcoma of the ovary (n=1). Total abdominal hysterectomy with bilateral salpingo-oophorectomy and adjuvant carboplatin and paclitaxel was evaluated on Symptom status and recurrence.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: